The study found that EPA and DHA have certain benefits on cognitive depression in patients with heart failure

Recently, a new study published in the Journal of heart failure by the American Heart Association found that EPA and DHA have some benefits for cognitive depression in patients with heart failure It is reported that the purpose of this randomized controlled trial (http:// is to evaluate the effect of omega-3 fatty acids (EPA and DHA) on depression and psychomotor symptoms in patients with chronic heart failure and depression Before the start of the trial, the researchers recruited a total of 108 subjects and randomly divided them into three groups The first group took 2G EPA / DHA supplement every day, the ratio of the two was 2:1, the second group took 2G EPA, the third group took the same amount of placebo as the control group The process lasted for 12 weeks, during which the researchers tested the subjects' blood (i.e omega-3 index, RBC levels of EPA and DHA) The results showed that the omega-3 index of the first group was 6.79%, that of the second group was 6.32%, and that of the control group was 4.61% The omega-3 index was 7.32%, 7.11% and 4.42% for those who completed the test and took at least 70% of the capsules This shows that the omega-3 index has dose compliance and can significantly improve the omega-3 index in just three months In addition, the researchers analyzed the social function of the subjects through SF-36 Questionnaire (http:// and the results showed that the social ability of the first group of subjects was significantly improved, as was the second group Studies have shown that there is a significant correlation between omega-3 index and cognitive depression index More specifically, a higher omega-3 index means a lower cognitive depression score on BDI-II, the most widely used Depression Scale (http:// Researchers said that in this study, it is uncertain whether EPA or DHA is more effective, but high levels of omega-3 fatty acids in the blood do improve the depressive symptoms of patients with heart failure and depression, which is a significant information for the future treatment of depression.